Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma
2005 (English)In: Surgery, ISSN 0039-6060, E-ISSN 1532-7361, Vol. 138, no 6, 986-993 p.Article in journal (Refereed) Published
BACKGROUND: Hepatic metastases from medullary thyroid carcinoma (MTC) may impair quality of life by hypercalcitonemia-associated diarrhea and pain. In this prospective study, the effect of selective arterial chemoembolization (SACE) was evaluated.
METHODS: Eleven patients with hepatic metastases from MTC received 1 to 9 courses of SACE using epirubicine. Symptomatic, biochemical, and morphologic responses on SACE were recorded.
RESULTS: Symptomatic response was observed in all symptomatic patients. However, biochemical and radiologic response occurred only in 6 patients. Liver function was not affected by SACE. One patient with unexpected concurrent pheochromocytoma metastases died after the first course. Development of side effects in the course was observed in 8 patients but were only World Health Organization grade 1. Patients' satisfaction with SACE was excellent. Long-term follow-up found 7 patients alive (1-72 months). Three patients died with tumor 6, 12, and 24 months after SACE, respectively.
CONCLUSION: SACE provided good symptom palliation for the majority of patients with hepatic metastases from MTC. However, transient remission or stabilization of hepatic metastases resulted in only 60%. Further studies using a randomized protocol are required.
Place, publisher, year, edition, pages
Elsevier, 2005. Vol. 138, no 6, 986-993 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-101422DOI: 10.1016/j.surg.2005.09.020PubMedID: 16360382OAI: oai:DiVA.org:liu-101422DiVA: diva2:666179
Discussion page 9932013-11-222013-11-222013-12-06Bibliographically approved